NewLink Genetics Corp. (NASDAQ:NLNK)’s share price rose 2.6% on Tuesday . The stock traded as high as $10.36 and last traded at $10.30, with a volume of 73,447 shares. The stock had previously closed at $10.04.

NLNK has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 5th. Robert W. Baird restated a “buy” rating on shares of NewLink Genetics Corp. in a research note on Monday, May 16th. Mizuho decreased their target price on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Stifel Nicolaus decreased their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Finally, Jefferies Group restated a “hold” rating and set a $10.00 target price on shares of NewLink Genetics Corp. in a research note on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $23.29.

The firm’s market capitalization is $296.06 million. The firm’s 50-day moving average price is $10.68 and its 200-day moving average price is $14.20.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. On average, equities research analysts predict that NewLink Genetics Corp. will post ($3.06) EPS for the current year.

An institutional investor recently raised its position in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP increased its position in shares of NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned about 0.17% of NewLink Genetics Corp. worth $1,765,000 at the end of the most recent reporting period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.